A biologics-and-GLP-1 “picks-and-shovels” leader whose upside depends on flawless new-capacity ramp and governance remediation.
Overview
Stevanato Group (STVN) is a critical infrastructure supplier to global pharma/biotech, providing primary containment (vials, cartridges, pre-fillable syringes), drug delivery systems, and the specialized engineering equipment used in fill-and-finish operations. The business is organized into Biopharmaceutical & Diagnostic Solutions (BDS) and Engineering; in FY2025 BDS contributed ~88% of revenue and Engineering ~12%. The company’s integrated model is strategically differentiated: it supplies both the container and the automated equipment/inspection systems that process it, embedding Stevanato in customer workflows and increasing switching costs. The core growth driver is the rapid adoption of Ready-to-Use (RTU) containers via EZ-fill and the mix shift toward High-Value Solutions (HVS) such as Nexa (mechanical strength for viscous/high-force biologics and GLP-1 applications) and Alba (chemical compatibility to protect sensitive biologics). FY2025 validated the mix-shift strategy: revenue grew ~7% reported (9% constant currency) to €1.186B and margins expanded (gross margin ~29%, adj. EBITDA margin ~25.1%) even as Engineering weakened. The multi-year thesis hinges on successful ramp and utilization of new capacity in Fishers, Indiana and Latina, Italy, which should enable utilization-driven margin expansion and stronger free cash flow as CapEx normalizes. Key investor watch-items are the timing of commercial ramp, recovery in Engineering, and remediation of disclosed internal control weaknesses.